Germany’s Merck KGaA has agreed to collaborate with Mammoth Biosciences on development, scale-up and commercial production of the US biotech’s CRISPR-based SARS CoV-2 diagnostic test. Mammoth recently secured funding from the US National Institute of Health’s RADx program to scale its CRISPR-based testing workflow.
The US Court of Appeals for the Federal Circuit on Sept. 28 set aside a decision of the US district court of New Jersey in Newark, reversing the district court’s earlier decision in favor of Biogen in a damages claim against Germany’s Merck Serono (known as EMD Serono in North America).
Under the name M Lab, Germany’s Merck has opened a new collaborative drug development center in Pudong, Shanghai, China. The facility with lab space of around 10,000 m2 is the largest of the pharmaceutical, chemicals and life science group’s nine such centers worldwide and is located in the heart of Shanghai’s biomedical sciences and research community.
